NCT00637611已完成4 期
Single-Center, Double-Blind, Randomized , Parallel Study Comparing Onset of Action, Efficacy & Safety of a Single-Dose of Fexofenadine HCl 180 mg vs Montelukast Na 10 mg & Placebo in Treating Seasonal Allergic Rhinitis Subjects in an Allergen Exposure Unit (Study I)
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- Sanofi
- 入组人数
- 1,010
- 试验地点
- 2
- 主要终点
- To determine the efficacy and onsets of action of single-dose fexofenadine hydrochloride 180 mg and montelukast sodium 10 mg relative to placebo in the treatment of subjects with moderately severe seasonal allergic rhinitis (SAR) in a controlled setting.
研究概览
简要总结
The primary objective of this study is to determine the efficacy and onsets of action of single-dose fexofenadine hydrochloride 180 mg and montelukast sodium 10 mg relative to placebo. Secondary objectives are to compare the safety and efficacy of fexofenadine hydrochloride 180 mg, montelukast sodium 10 mg, and placebo
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 15 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male and female subjects, 15 years of age or older
- •History of seasonal allergic rhinitis (SAR) during the fall pollen season, for at least the previous 2 years
- •History of having a positive response to antihistamines for symptoms of SAR
- •Must be skin test positive to ragweed within the last 15 months with at least a moderate reaction as defined by a wheal 7 mm greater than the diluent wheal after intradermal skin test or a wheal 5 mm greater than the diluent wheal after skin prick test. A skin test performed in the previous 15 months may be used to qualify the patient if it was performed at the investigator's site and recorded in the subject's medical record
- •All females must have negative urine pregnancy test at screening visit
- •Willing and able to adhere to visit schedules and all study requirements
排除标准
- •Clinically significant medical condition (such as cardiovascular, hepatic, neurologic, hematological, renal, gastrointestinal, endocrine, or other major systemic disease), which, in the judgment of the investigator, might interfere with the study, require treatment or make implementation of the protocol or interpretation of the study results difficult
- •Asthma that requires treatment with medication other than an inhaled, short-acting beta agonist or asthma that will be exacerbated by exposure to ragweed pollen
- •Pregnancy or breast-feeding
- •History of hypersensitivity to the study medications or to drugs with similar chemical structures
- •Nasal structural abnormalities, including large nasal polyps or marked septal deviation, that significantly interfere with nasal air flow
- •Likelihood of requiring treatment during the study period with drugs not permitted by the study protocol
- •Upper or lower respiratory infection within 14 days of the first priming visit
- •Diagnosis of sinusitis within 30 days of the first priming visit
- •Immunotherapy, except those on a constant dose of immunotherapy that will be maintained throughout the study
- •Treatment with any investigational drug in the last 30 days before study entry
- •Recent history of drug or alcohol abuse
- •Mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study
- •Unlikelihood to comply with protocol such as those with uncooperative attitude or the inability to return for follow-up visits or to complete the study
- •Subjects who were randomized into this trial will not be eligible to participate in another fexofenadine hydrochloride 180 mg vs montelukast sodium 10 mg onset of action study (planned to be conducted in 2003)
- •Subjects who are research employees or relatives of study site staff involved in this study or those who have or will read the protocol
结局指标
主要结局
To determine the efficacy and onsets of action of single-dose fexofenadine hydrochloride 180 mg and montelukast sodium 10 mg relative to placebo in the treatment of subjects with moderately severe seasonal allergic rhinitis (SAR) in a controlled setting.
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Evaluation of Possible Effects on the QTc Interval of CHF 4226 pMDI in Healthy VolunteersChronic Obstructive Pulmonary DiseaseNCT00777595Chiesi Farmaceutici S.p.A.47
已完成
1 期
To Evaluate the Pharmacokinetics and Safety/Tolerability of Lacosamide in 3 Dosages in Healthy Male Korean SubjectsEpilepsyNCT01450111UCB Pharma51
已完成
1 期
Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of BIIB033 in Healthy Japanese ParticipantsCentral Nervous System (CNS) Demyelinating DiseaseMultiple SclerosisNCT02641041Biogen24
已完成
4 期
Efficacy and Safety of a Multi-dose Regimen of Mebendazole Against Hookworm in ChildrenHookwormNCT03245398Jennifer Keiser186
已完成
3 期
Dose Finding of Quetiapine Fumarate 200mg vs 400mg in First Episode PsychosisPsychosisNCT00449397AstraZeneca150